Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Diabetes

Dapagliflozin—redefining treatment of T2DM?

Nature Reviews Endocrinology volume 7, pages 696–697 (2011)Cite this article

Subjects

Glycemic control for many patients with type 2 diabetes mellitus (T2DM) is elusive, and the adverse effects of treatment, including hypoglycemia and weight gain, are partially culpable. Until recently, glycosuria has been regarded only as a consequence of T2DM, but dapagliflozin employs glycosuria as a mechanism of treatment. Will this paradigm shift gain acceptance?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ferrannini, E., Ramos, S. J, Salsali, A., Tang, W. & List, J. F. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33, 2217–2224 (2010).

    Article  Google Scholar 

  2. Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A. & List, J. F. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 375, 2223–2233 (2010).

    Article  CAS  Google Scholar 

  3. Strojek, K. et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomised, 24-week, double-blind, placebo-controlled trial. Diabetes Obes. Metab. 13, 928–938 (2011).

    Article  CAS  Google Scholar 

  4. Nauck, M. A. et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin. Diabetes Care 34, 2015–2022 (2011).

    Article  CAS  Google Scholar 

  5. Nathan, D. M. et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32, 193–203 (2009).

    Article  CAS  Google Scholar 

  6. FDA. FDA Briefing Document. NDA 202293. Dapagliflozin Tablets, 5 and 10 mg. Sponsor: Bristol-Myers Squibb. Advisory Committee Meeting, July 19, 2011 [online] (2011).

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology and Metabolism, University of California, San Diego and VA San Diego, 3350 La Jolla Village Drive, San Diego, 92161, CA, USA

    Edward C. Chao

Authors
  1. Edward C. Chao
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chao, E. Dapagliflozin—redefining treatment of T2DM?. Nat Rev Endocrinol 7, 696–697 (2011). https://doi.org/10.1038/nrendo.2011.177

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2011.177

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing